BioCentury | Apr 14, 2020
Finance

Cerevance raises $45M toward series B, plans four more clinical programs for CNS disorders

With one CNS program in Phase II and four more approaching the clinic’s doorstep, Cerevance has raised the first $45 million of a series B round that could reach $60 million -- although the COVID-19...
BC Innovations | Jan 25, 2018
Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
BC Week In Review | Dec 9, 2016
Company News

Novartis, Lightstone, Cerevance deal

Takeda will grant neurology newco Cerevance a license to preclinical and clinical CNS programs and provide the company with lab space and personnel from Takeda's former operations in Cambridge, U.K. Cerevance launched in December with...
BC Extra | Dec 2, 2016
Financial News

Takeda, Lightstone back CNS newco Cerevance

Neurology newco Cerevance LLC (Cambridge, Mass.) launched with $36 million, including a $21.5 million series A from co-leaders Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Lightstone Ventures. Cerevance declined to name the source of the balance,...
BioCentury | May 30, 2016
Finance

It takes a village

5AM Ventures isn't about to jump on the bandwagon with other early stage biotech venture firms that are raising large funds with the goal of forming smaller syndicates and retaining larger ownership stakes. Instead, the...
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

After spending a decade growing the company via acquisition, Takeda Pharmaceutical Co. Ltd. is now focused on getting its costs in line with its global pharma peers. But to grow EPS in line with Street...
BioCentury | May 6, 2013
Strategy

Doubling down in diabetes

Against a backdrop of flattening sales of its only marketed diabetes drugs and a new class of oral drugs - SGLT2s - entering the market from competitors, Merck & Co. Inc. appears to be shoring up its...
BC Week In Review | Mar 25, 2013
Company News

Takeda, Scripps Research Institute deal

Takeda and Scripps expanded a 2010 discovery deal to include additional undisclosed targets in new undisclosed therapeutic areas. The partners are using the institute's high throughput screening technology to discover compounds against undisclosed targets from...
BioCentury | Dec 3, 2012
Strategy

Takeda samples, then buys

After first making a venture investment in Envoy Therapeutics Inc. in 2009 and then sampling its wares under a 2010 target discovery deal, Takeda Pharmaceutical Co. Ltd. has taken the next step and acquired the...
BC Week In Review | Nov 12, 2012
Company News

Envoy Therapeutics, Takeda deal

Takeda will acquire partner Envoy for up to $140 million in cash, including an upfront payment and preclinical milestones. Takeda, which has a 12.5% stake in Envoy, will gain the biotech's bacTRAP technology and preclinical...
Items per page:
1 - 10 of 21
BioCentury | Apr 14, 2020
Finance

Cerevance raises $45M toward series B, plans four more clinical programs for CNS disorders

With one CNS program in Phase II and four more approaching the clinic’s doorstep, Cerevance has raised the first $45 million of a series B round that could reach $60 million -- although the COVID-19...
BC Innovations | Jan 25, 2018
Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
BC Week In Review | Dec 9, 2016
Company News

Novartis, Lightstone, Cerevance deal

Takeda will grant neurology newco Cerevance a license to preclinical and clinical CNS programs and provide the company with lab space and personnel from Takeda's former operations in Cambridge, U.K. Cerevance launched in December with...
BC Extra | Dec 2, 2016
Financial News

Takeda, Lightstone back CNS newco Cerevance

Neurology newco Cerevance LLC (Cambridge, Mass.) launched with $36 million, including a $21.5 million series A from co-leaders Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Lightstone Ventures. Cerevance declined to name the source of the balance,...
BioCentury | May 30, 2016
Finance

It takes a village

5AM Ventures isn't about to jump on the bandwagon with other early stage biotech venture firms that are raising large funds with the goal of forming smaller syndicates and retaining larger ownership stakes. Instead, the...
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

After spending a decade growing the company via acquisition, Takeda Pharmaceutical Co. Ltd. is now focused on getting its costs in line with its global pharma peers. But to grow EPS in line with Street...
BioCentury | May 6, 2013
Strategy

Doubling down in diabetes

Against a backdrop of flattening sales of its only marketed diabetes drugs and a new class of oral drugs - SGLT2s - entering the market from competitors, Merck & Co. Inc. appears to be shoring up its...
BC Week In Review | Mar 25, 2013
Company News

Takeda, Scripps Research Institute deal

Takeda and Scripps expanded a 2010 discovery deal to include additional undisclosed targets in new undisclosed therapeutic areas. The partners are using the institute's high throughput screening technology to discover compounds against undisclosed targets from...
BioCentury | Dec 3, 2012
Strategy

Takeda samples, then buys

After first making a venture investment in Envoy Therapeutics Inc. in 2009 and then sampling its wares under a 2010 target discovery deal, Takeda Pharmaceutical Co. Ltd. has taken the next step and acquired the...
BC Week In Review | Nov 12, 2012
Company News

Envoy Therapeutics, Takeda deal

Takeda will acquire partner Envoy for up to $140 million in cash, including an upfront payment and preclinical milestones. Takeda, which has a 12.5% stake in Envoy, will gain the biotech's bacTRAP technology and preclinical...
Items per page:
1 - 10 of 21